Nov. 27 (Bloomberg) –- GlaxoSmithKline completed an initial step toward making an Ebola vaccine widely available after a study with 20 healthy adults produced responses from the immune system and didn’t raise safety concerns. Bloomberg Intelligence’s Sam Fazeli discusses the impact of the study with Anna Edwards on “Countdown.” (Source: Bloomberg)
You're really amuzing. Why do you think this is such a great short? I recently lost y ABBV by selling covered calls and was looking for a big pharma with good product line, good P/E and good divi. I bought Glaxo for 45.50 a few days ago.
Why would they want to? This whole tax scam seems to be a refuge for sub-par managers who can't develop their companies in more traditional ways. I like GlaxoSmith Kline for their products, P/E and dividends. My target price is in the low 50's by the end of March 2015.
as of November 26, with stock at 46.50, that's not working very well. Do you have any other short ideas? I have some money to invest on the long side. The short money in GSK was made several months ago; you are late to the party.
The problem with those who hope for "a cure for cancer" is the failure to recognize that this is a symptom not a disease. Cancer is caused by more than one entity showing up as (not in all cases) a malignant neoplasm. Treatment depends on location, type of cell involved and stage of progression. I do not believe there will ever be a single cure for the symptom commonly called cancer.
Seems to me GSK getting rid of Cancer drug unit could be a good thing. As long as I have been alive, we are searching for a cure for cancer. It looks like it's not achievable. Cancer is cured by food and genetics, if anything. Overdosing on Broccoli for example and choosing your parents well.
Anyway, I lean to vote Yes. What do others think?
Sorry folks, I had the wrong msg. board.
Pfizer was my target.
Go back 10 years and you'll see the price was just about the same as it is now.
Except for dividends, this has been a dead money stock for years.
I bought in July this year hoping for a tie-up with AZN and Read screwed that one up royally like he screwed up selling the consumer goods division to JNJ.
Go ahead,see what JNJ has done with that group.
I have no faith in Read's ability to get anything done for shareholders except for himself.
I think he should be replaced.
Nice call! I was on the edge to buy a little, but didn't. I just cant' see this being an affordable treatment for the masses. It is a band aid, not a cure.